PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 25, 2007Diabetes Care471 citationsOpen Access

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

TVTina VilsbøllMZMilan ZdravkovicTLT Le-Thi

Key Points

Key points are not available for this paper at this time.

Abstract

iraglutide is a long-acting human glucagon-like peptide-1 (GLP-1) analog (1-4), and the current study was undertaken to evaluate efficacy and safety after 14 weeks' treatment with liraglutide in patients with type 2 diabetes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Vilsbøll et al. (2007) studied this question.

synapsesocial.com/papers/69d7f5f761e2ce1627d186e1https://doi.org/10.2337/dc06-2593
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects1997 · 674 citations
  2. 2Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.1998 · 8,424 citations
  3. 3Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes2006 · 143 citations
  4. 4The long-acting GLP-1 analogue, liraglutide, increases beta cell numbers during early human development2005 · 6 citations
  5. 5Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration2000 · 701 citations